EcoDrugPlus

Protein Kinase D1

Ensembl ID : ENSMZEG00005000936
Gene Symbol: PRKD1
3 Cross references
201 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSMZEG00005013100
Gene Symbol: PRKD3
4 Cross references
201 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSMZEG00005005812
Gene Symbol: PRKD3
3 Cross references
209 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSMZEG00005011480
Gene Symbol: PRKDC
3 Cross references
184 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSMZEG00005002547
Gene Symbol: PPP3CA
4 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSMZEG00005026719
Gene Symbol: PTK2
3 Cross references
246 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSMZEG00005015713
Gene Symbol: PTK2B
3 Cross references
195 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSMZEG00005008096
Gene Symbol: PTPN11
3 Cross references
250 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11a

Ensembl ID : ENSMZEG00005026048
Gene Symbol: PTPN11A
1 Cross references
250 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSMZEG00005020444
Gene Symbol: PTPRB
4 Cross references
203 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSMZEG00005016131
Gene Symbol: PTPRB
4 Cross references
189 Possible Orthologues:

Protein-Tyrosine Kinase 6

Ensembl ID : ENSMZEG00005026789
Gene Symbol: LOC101476004
3 Cross references
159 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).